Torres-Ruesta A
Heterologous mRNA vaccine boosters induce a stronger and longer-lasting antibody response against Omicron XBB variant
The SARS-CoV-2 Omicron recombinant XBB subvariant was first detected in September 2022, and rapidly spread across South-East Asia, notably overtaking BA.5 to become the dominant variant in Singapore.
ReadResistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians
SARS-CoV-2 was first detected in late December 2019, however, in the few months that followed, the resultant COVID-19 disease has developed into a devastating pandemic around the world [[1]]. This has led to a race to produce a safe and efficacious vaccine in record time.
ReadHuman neutralising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant
Objectives: The emergence of a SARS-CoV-2 variant with a point mutation in the spike (S) protein, D614G, has taken precedence over the original Wuhan isolate by May 2020. With an increased infection and transmission rate, it is imperative to determine whether antibodies induced against the D614 isolate may cross-neutralise against the G614 variant.
Read